(Q37427326)

20 August 2017

0 references

Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload (English)

1 reference

20 August 2017

0 references

3

Elliott Vichinsky

1 reference

20 August 2017

1

Ali Taher

1 reference

20 August 2017

Maria D Cappellini

2

1 reference

20 August 2017

Renzo Galanello

4

1 reference

20 August 2017

Antonio Piga

5

1 reference

20 August 2017

Tomasz Lawniczek

6

1 reference

20 August 2017

Joan Clark

7

1 reference

20 August 2017

Dany Habr

8

1 reference

20 August 2017

John B Porter

9

1 reference

20 August 2017

language of work or name

English

0 references

publication date

18 September 2009

1 reference

British Journal of Haematology

20 August 2017

1 reference

20 August 2017

147

1 reference

20 August 2017

5

1 reference

20 August 2017

752-759

1 reference

Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779992

Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779992

A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779992

Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779992

A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779992

Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779992

Iron-chelating therapy and the treatment of thalassemia.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779992

Serum ferritin concentration in sickle cell crisis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779992

Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2779992

Survival in medically treated patients with homozygous beta-thalassemia

2 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19764988

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19764988

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/J.1365-2141.2009.07908.X

1 reference

20 August 2017

1 reference

20 August 2017

PubMed publication ID

19764988

1 reference